Telehealth treatment showed a measurable effect, but not on the trial’s main target
A randomized clinical trial published in Hepatology suggests that a structured telehealth program can help people with chronic liver disease cut back on alcohol use, a meaningful result in a population where continued drinking can sharply worsen outcomes. The study did not show a difference on its primary endpoint, but it did find a sustained reduction in drinks per week over six months compared with usual care.
The trial evaluated a stepped alcohol treatment program delivered remotely. Participants first received three motivational interviewing sessions. If they had not reduced drinking by month three, they were referred to addiction medicine. Researchers compared that approach with usual care in 157 adults who had chronic liver disease and unhealthy alcohol use.
Unhealthy alcohol use in the study included intake above weekly or daily thresholds for men and women, as well as heavy episodic drinking. That matters because chronic liver disease can progress under continued alcohol exposure even when a patient’s underlying condition is not alcohol-related. Guidelines already recommend offering integrated alcohol interventions to these patients, but putting those programs into practice inside liver clinics has remained difficult.
The new findings do not amount to a clean win for telehealth intervention across every measure. The primary outcome was the percentage of alcohol use kept below a moderate level, and on that measure the stepped treatment was not different from usual care. But on a secondary outcome, weekly drinking fell more in the telehealth group at both three and six months. The estimated treatment effects reported by the researchers were similar at those checkpoints, suggesting the reduction was not just a short-lived early response.
That mixed result is important. It means the study does not show a broad transformation in drinking behavior across all measures, but it does provide evidence that telehealth support can produce a clinically relevant reduction in overall consumption. In addiction care and liver medicine, that distinction matters: reducing total alcohol intake can still lower risk, improve disease management, and create a path toward abstinence for some patients.
Why liver clinics are paying closer attention to alcohol care
Chronic liver disease is often managed over long periods, and many patients face barriers to consistent behavioral treatment. Specialist addiction care may be difficult to access, patients may live far from major centers, and liver practices may not have embedded counseling programs. Telehealth changes some of that equation by making repeated contact easier without requiring a separate clinic workflow or travel burden.
In this trial, 81 participants were assigned to stepped alcohol treatment and 76 to usual care. By month six, 30-day abstinence rates were 29% in the telehealth group and 18% in the usual-care group. The study summary did not present that as the primary basis for success, but it adds context to the broader pattern: the intervention appears to have helped a larger share of patients either stop drinking or reduce use substantially over time.
The researchers also found that baseline motivation to reduce alcohol use was positively associated with treatment response. That finding reinforces a long-standing challenge in behavioral medicine. A program may be effective on average, but its impact can depend heavily on where patients are when they enter care. For clinicians, that suggests screening for readiness to change may help identify who is most likely to benefit quickly and who may need more intensive support earlier.
The stepped design of the program is also notable. Rather than starting every patient with specialty addiction treatment, the intervention began with motivational interviewing and escalated only if drinking had not fallen by month three. That structure mirrors how many health systems are trying to deliver behavioral care more efficiently: provide a lower-burden first step, then reserve specialist resources for patients who do not respond.
Telehealth has already become a standard part of many medical specialties, but evidence for specific treatment pathways still needs to be built condition by condition. In liver disease, that evidence base has lagged behind the need. The trial therefore adds more than a simple outcome measure; it offers a tested model that clinics could adapt if they are trying to close the gap between guideline recommendations and what patients actually receive.
What the study does and does not establish
The most careful reading of the trial is that telehealth stepped treatment improved some important drinking outcomes without proving superiority on the study’s main endpoint. That should temper overstatement. It is not evidence that remote counseling alone solves alcohol-related risk in chronic liver disease, and it does not show that every patient will reach low-risk consumption levels through this model.
At the same time, the secondary outcome results were durable through six months and remained significant after controlling for covariates, according to the study summary. In practical terms, that strengthens the case that the difference was not just a statistical artifact of baseline differences between groups.
The study also arrives amid a broader effort to integrate addiction treatment into non-psychiatric care settings. Liver clinics are a particularly important setting because alcohol use can directly alter disease progression, transplant candidacy, hospitalization risk, and long-term survival. An intervention that can be delivered remotely and folded into ongoing specialty care may therefore have outsized value even if its effects are moderate rather than dramatic.
Disclosure details are also part of the record. Several authors reported ties to pharmaceutical and biopharmaceutical industries. That does not negate the findings, but it is relevant context for readers assessing the research environment around the study.
For now, the strongest conclusion is pragmatic: telehealth-based stepped alcohol treatment appears to help some patients with chronic liver disease reduce weekly drinking, and it may offer clinics a workable route to expand support where integrated alcohol care is still rare. Future studies will need to clarify which patients benefit most, whether effects hold over longer follow-up, and how this model performs when implemented outside a controlled trial.
In a field where perfect adherence and universal abstinence are hard to achieve, incremental but durable reductions can still matter. This study suggests remote, structured intervention deserves a more serious place in liver care than it has had so far.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
